Malaria Vaccine Development Program (MVDP)

Current Focus

The USAID MVDP has two main thrusts, designed to fill the most important gaps in the global malaria vaccine development effort:

• The development of protein-recombinant vaccines to protect residents in endemic areas. This program, which is accomplished primarily through an interagency agreement with the Walter Reed Army Institute of Research, focuses on the blood stages of the parasite, which are responsible for disease and are uniquely important for the USAID target population.
  


• The development of adenovirus-vectored vaccines. This technology holds great promise as a more effective means of producing the required immune response to protect recipients from disease. This work is through an interagency agreement with the Naval Medical Research Center.
  


• See the 2006 USAID Research and Development Report to Congress for more details.